Document is current
Any future updates will be listed below
-
Authors
Alghamdi, Ahmed
Balkhi, Bander
Altowaijri, Abdulaziz
Al-shehri, Nasser
Ralph, Lewis
Marriott, Emily-Ruth
Urbich, Michael
Aljanad, Fawaz
Aziziyeh, Rima https://orcid.org/0000-0003-2651-3069
- License Information
-
More Information
Article History
Accepted: 10 August 2021
First Online: 28 September 2021
Declarations
:
: The study was funded by Amgen Inc.
: BresMed was contracted by Amgen for the adaptation of the global model to Saudi settings. Ahmed Alghamdi, Bander Balkhi, Abdulaziz Altowaijri, and Nasser Al-shehri received consultation fees from BresMed. Rima Aziziyeh, Fawaz Aljanad, and Michael Urbich are employees of Amgen who are the manufacturers of evolocumab. Emily-Ruth Marriott and Lewis Ralph are employees of BresMed.
: Not applicable
: Not applicable
: Not applicable
: Not applicable
: All authors were involved in the study conception and the analysis and interpretation of data as well as the drafting of the manuscript. All authors have read and approved this version of the manuscript. All authors agree to be accountable for all aspects of the work.
